**Highlights of This Issue 1345**

**SPECIAL FEATURES**

1347

**Editors’ Note**

Introducing *New Strategies in…*

James L. Abbruzzese, Alexander M.M. Eggermont, and Eric H. Rubin

**CCR New Strategies**

1348

New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance

Brian I. Rini

**CCR Translations**

1355

Does Lapatinib Work against HER2-negative Breast Cancers?

Ingrid A. Mayer and Carlos L. Arteaga

See article p. 1486

**Statistics in Clinical Cancer Research**

1358

Testing Clonal Relatedness of Tumors Using Array Comparative Genomic Hybridization: A Statistical Challenge

Irina Ostrovnaya and Colin B. Begg

**CCR Drug Updates**

1368

Everolimus

Peter J. Houghton

**Molecular Pathways**

1373

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

Marcia R. Campbell, Dhara Amin, and Mark M. Moasser

1384

Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward

David G. Menter, Richard L. Schilsky, and Raymond N. DuBois

**HUMAN CANCER BIOLOGY**

1391

High-Resolution Array Comparative Genomic Hybridization in Sporadic and Celiac Disease–Related Small Bowel Adenocarcinomas

Begoña Diosdado, Tineke E. Buffart, Russell Watkins, Beatriz Carvalho, Bauke Ylstra, Marianne Tijssen, Anne S. Bolijn, Fraser Lewis, Karen Maude, Caroline Verbeke, Iris D. Nagtegaal, Heike Grabsch, Chris J.J. Mulder, Phil Quirke, Peter Howdle, and Gerrit A. Meijer

1402

Critical Role of Gε13 and Gα13 for Human Small Cell Lung Cancer Cell Proliferation *In vitro* and Tumor Growth *In vivo*

Marius Grzelinski, Olaf Pinkenburg, Thomas Büch, Maike Gold, Stefanie Stohr, Hermann Kalwa, Thomas Gudermann, and Achim Aigner

1416

Association of TGF-β1 Genetic Variants with HPV16-positive Oropharyngeal Cancer

Xiaoxiang Guan, Erich M. Sturgis, Dapeng Lei, Zhensheng Liu, Kristina R. Dahlstrom, Qingyi Wei, and Guojun Li

1423

ZIP4 Regulates Pancreatic Cancer Cell Growth by Activating IL-6/STAT3 Pathway through Zinc Finger Transcription Factor CREB

Yuqing Zhang, Uddalak Bharadwaj, Craig D. Logsdon, Changyi Chen, Qizhi Yao, and Min Li

1431

Neuroblastoma Progression Correlates with Downregulation of the Lymphangiogenesis Inhibitor sVEGFR-2

Jürgen Becker, Helena Pavlakovic, Fabian Ludewig, Fabiola Wilting, Herbert A. Weich, Romulo Albuquerque, Jayakrishna Ambati, and Jörg Wilting
CANCER THERAPY: PRECLINICAL

1442 Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy
Xin Dong, Jun Guan, John C. English, Julia Flint, John Yee, Kenneth Evans, Nevin Murray, Calum MacAulay, Raymond T. Ng, Peter W. Gout, Wan L. Lam, Janessa Laskin, Victor Ling, Stephen Lam, and Yuzhuo Wang

1452 Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer
Stefanie Hammer, Anette Sommer, Iduna Fichtner, Michael Becker, Jana Rolff, Johannes Merk, Ulrich Klar, and Jens Hoffmann

1466 An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity
Zachary Hartman, Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, Dong-Wan Kim, Wenle Xia, Neil Spector, Jeffrey Marks, William Barry, Amy Hobieka, Gayathri Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, and Timothy M. Clay

1478 Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma
Radhika Iyer, Audrey E. Evans, Xiaoxue Qi, Ruth Ho, Jane E. Minturn, Huaqing Zhao, Naomi Balamuth, John M. Maris, and Garrett M. Brodeur

1486 Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance

1498 Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase 1 Evaluation
Douglas H. Thamm, Ilene D. Kurzman, Mike A. Clark, E.J. Ehrhart III, Susan L. Kraft, Daniel L. Gustafson, and David M. Vail

IMAGING, DIAGNOSIS, PROGNOSIS

1509 Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safra, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, and Richard S. Finn

1520 Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
Toshihiko Ishii, Takashi Ishida, Atae Utsunomiya, Atsushi Inagaki, Hiroki Yano, Hirokazu Komatsu, Shinsuke lida, Kazunori Imada, Takashi Uchiyama, Shiro Akinaga, Kenya Shitara, and Ryuzu Ueda

1532 Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature
Katie De Preter, Joëlle Vermeulen, Benedikt Brors, Olivier Delattre, Angelika Eggert, Matthias Fischer, Isabelle Janoueix-Lerosey, Cinzia Lavrino, John M. Maris, Siene Jerbi, Akira Nakagawara, André Oberschütz, Miki Ohira, Gudrun Schleiermacher, Alexander Schramm, Johannes H. Schulte, Qun Wang, Frank Westermann, Frank Speleman, and Jo Vanesompele

1542 Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Imaging Biomarkers

1553 Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer
Sarah Minner, Birte Jessen, Lars Stiedenroth, Eike Burandt, Jens Köllermann, Martina Mirlacher, Andreas Erbersdobler, Christian Eichelberg, Margit Fisch, Tim Henrik Brümmendorf, Carsten Bokemeyer, Ronald Simon, Thomas Steuber, Markus Graeven, Hartwig Huland, Guido Sauter, and Thorsten Schlomm
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival

Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab
Howard M. Stern, Mary Padilla, Klaus Wagner, Lukas Amler, and Avi Ashkenazi

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendrogial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorn, Pieter Wesseling, Marc Frenay, Coes C. Tijsen, Denis Lacombe, Ahmed Idahlal, Ronald van Marion, Johan M. Kros, Winand N.M. Dinjens, Thierry Gorlia, and Marc Sanson

Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
Josefine Becker, Lambert Skoog, Tommy Fonander, Bo Nordenskjöld, and Olle Stål

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 704028), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
Hui Huang, Michael Menefee, Maureen Edgerly, Sen Zhuang, Herb Kotz, Marianne Poruchynsky, Lyn Mickley Huff, Susan Bates, and Tito Fojo

Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome–Encoded Minor Histocompatibility Epitopes
Yishai Ofran, Haesook T. Kim, Vladimir Brusic, Loren Blake, Michael Mandrell, Catherine J. Wu, Stefanie Sarantopoulos, Roberto Bellucci, Derin B. Keskin, Robert J. Soiffer, Joseph H. Antin, and Jerome Ritz
The featured image is a lung adenocarcinoma stained with a novel, highly sensitive and specific antibody recognizing the ALK oncoprotein (brown staining) and counterstained with hematoxylin (blue staining). The tumor was shown to harbor a rearrangement of the ALK locus by genetic analysis. This assay will facilitate the routine identification of ALK-rearranged lung adenocarcinomas in clinical practice and detect lung cancers that may be responsive to ALK inhibitors. For details, see the article by Mino-Kenudson and colleagues on page 1561 of this issue.

Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma
Thomas Puchalski, Uma Prabhakar, Qun Jiao, Birge Berns, and Hugh M. Davis

Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
Christy Ralph, Eyad Elkord, Deborah J. Burt, Jackie F. O’Dwyer, Eric B. Austin, Peter L. Stern, Robert E. Hawkins, and Fiona C. Thistlethwaite

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

Implications of LINE1 Methylation for Bladder Cancer Risk in Women

Is High-Grade Prostate Cancer Easier to Find in Smaller Prostates Because There Is More High-Grade Disease to Find? - Letter
Patrick Walsh

Correction: PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

Correction: MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival

About the Cover

The featured image is a lung adenocarcinoma stained with a novel, highly sensitive and specific antibody recognizing the ALK oncoprotein (brown staining) and counterstained with hematoxylin (blue staining). The tumor was shown to harbor a rearrangement of the ALK locus by genetic analysis. This assay will facilitate the routine identification of ALK-rearranged lung adenocarcinomas in clinical practice and detect lung cancers that may be responsive to ALK inhibitors. For details, see the article by Mino-Kenudson and colleagues on page 1561 of this issue.